Supernus has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Supernus, 2018, MAR 1, 2018, View Source [SID1234524319]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 1, 2018 – AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX) reported that the company’s Chief Executive Officer Michael D. West, Ph.D. will participate at three upcoming conferences: the Mauldin Economics Strategic Investment Conference, March 6-9 in San Diego; Undoing Aging, March 15-17 in Berlin, Germany; and the 10th World Congress and Expo on Cell & Stem Cell Research, March 19-21 in New York City (Press release, BioTime, MAR 1, 2018, View Source;p=RssLanding&cat=news&id=2335597 [SID1234524296]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Further details follow:

The Mauldin Economics Strategic Investment Conference
March 6-9 in San Diego, California
AgeX session: Wednesday, March 7, 1:50pm PST
Dr. West and AgeX’s VP of New Technology Discovery Aubrey de Grey, Ph.D. will participate on the Biotech panel, along with Eric Verdin, M.D., President and CEO of the Buck Institute for Research on Aging.

Undoing Aging
March 15-17 in Berlin, Germany
AgeX presentation: Friday, March 16 at 11:30am CET
Dr. West will discuss the prospect of using stem cell-derived cells for the treatment of age-related degenerative conditions.
The conference is being organized in part by Dr. de Grey in his capacity as Chief Science Officer of the SENS Research Foundation, which is co-sponsoring the event.

The 10th World Congress and Expo on Cell & Stem Cell Research
March 19-21 in New York City
AgeX presentation: Tuesday, March 20 at 9:00am EDT
Dr. West will deliver a presentation titled, "Induced tissue regeneration (iTR): Leveraging the unique regenerative potential of pluripotent stem cell-derived therapeutics."

A copy of Dr. West’s presentations will be available on the AgeX website.

Intrexon has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Intrexon, 2018, MAR 1, 2018, View Source [SID1234524278]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ziopharm has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Ziopharm, 2018, MAR 1, 2018, View Source [SID1234524335]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 1, 2018 ChemoCentryx, Inc., (Nasdaq:CCXI), reported that the Company’s fourth quarter 2017 financial results will be released before market open on Friday, March 9, 2018 (Press release, ChemoCentryx, MAR 1, 2018, View Source [SID1234524297]). ChemoCentryx executive management will host a conference call beginning at 8:30 a.m. Eastern Time on March 9, 2018 to discuss these results and to answer questions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 4887708. A live and archived audio webcast can be accessed through the Investors section of the Company’s website at www.ChemoCentryx.com. The archived webcast will remain available on the Company’s website for fourteen (14) days following the call.